- Home
- ALVO vs OGN Comparison
ALVO vs OGN Comparison
Compare ALVO & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVO
- OGN
- Stock Information
- Founded
- ALVO 2013
- OGN 1923
- Country
- ALVO Luxembourg
- OGN United States
- Employees
- ALVO N/A
- OGN N/A
- Industry
- ALVO Biotechnology: Pharmaceutical Preparations
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- ALVO Health Care
- OGN Health Care
- Exchange
- ALVO Nasdaq
- OGN Nasdaq
- Market Cap
- ALVO 3.4B
- OGN 3.9B
- IPO Year
- ALVO N/A
- OGN N/A
- Fundamental
- Price
- ALVO $12.60
- OGN $14.95
- Analyst Decision
- ALVO Buy
- OGN Hold
- Analyst Count
- ALVO 1
- OGN 3
- Target Price
- ALVO $18.00
- OGN $21.33
- AVG Volume (30 Days)
- ALVO 145.6K
- OGN 4.4M
- Earning Date
- ALVO 11-13-2024
- OGN 02-13-2025
- Dividend Yield
- ALVO N/A
- OGN 7.49%
- EPS Growth
- ALVO N/A
- OGN 120.97
- EPS
- ALVO N/A
- OGN 5.04
- Revenue
- ALVO $393,919,000.00
- OGN $6,409,000,000.00
- Revenue This Year
- ALVO $398.12
- OGN $3.11
- Revenue Next Year
- ALVO $44.73
- OGN $1.84
- P/E Ratio
- ALVO N/A
- OGN $2.97
- Revenue Growth
- ALVO 517.92
- OGN 4.21
- 52 Week Low
- ALVO $9.15
- OGN $13.65
- 52 Week High
- ALVO $18.00
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- ALVO 63.60
- OGN 44.66
- Support Level
- ALVO $11.70
- OGN $13.87
- Resistance Level
- ALVO $12.25
- OGN $14.92
- Average True Range (ATR)
- ALVO 0.28
- OGN 0.58
- MACD
- ALVO 0.13
- OGN 0.04
- Stochastic Oscillator
- ALVO 94.28
- OGN 51.92
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.